Kymera Therapeutics (KYMR) has announced a new collaboration with Gilead Sciences (GILD, Financial) focused on the development of a CDK2 molecular glue degrader. This agreement is part of Kymera's strategic updates, which have also seen Sanofi shifting its priorities from developing the KT-474 IRAK4 degrader to advancing a next-generation compound, KT-485, scheduled to begin Phase 1 trials next year.
Despite the setback with KT-474, this collaboration with Gilead could prove lucrative for Kymera, offering up to $85 million in upfront payments and options. Market analysts view this as a buying opportunity, as they consider the current stock price undervalued, especially given the potential of Kymera's broader pipeline and additional milestone payments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Gilead Sciences Inc (GILD, Financial) is $116.67 with a high estimate of $140.00 and a low estimate of $93.00. The average target implies an upside of 11.04% from the current price of $105.07. More detailed estimate data can be found on the Gilead Sciences Inc (GILD) Forecast page.
Based on the consensus recommendation from 30 brokerage firms, Gilead Sciences Inc's (GILD, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Gilead Sciences Inc (GILD, Financial) in one year is $84.02, suggesting a downside of 20.03% from the current price of $105.065. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Gilead Sciences Inc (GILD) Summary page.
